DURECT Corporation news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

DRRX 0.797 -0.013 (-1.64%)
price chart
Durect Corporation Stock Downgraded (DRRX)
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk ...
Related articles »  
DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings ...
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products.
Related articles »  
Why DURECT Corporation Shares Were Walloped
What: Shares of DURECT (NASDAQ: DRRX ) , a specialty pharmaceutical company that develops proprietary anti-abuse drug technology platforms, sank as much as 32% after it received a complete response letter from the Food and Drug Administration for ...
DURECT Corporation (DRRX) news: 10 Reasons To Buy Durect Right Now  Seeking Alpha
DURECT Receives Complete Response Letter from FDA for POSIDUR ...  PR Newswire (press release)
Related articles »  
DURECT Corporation Announces First Quarter 2014 Financial Results and ...
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products.
Related articles »  
3 Reasons To Buy Durect Corporation
Durect Corporation (NASDAQ:DRRX) is a specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies.
Durect Corporation Stock Upgraded (DRRX)
NEW YORK ( TheStreet) -- Durect Corporation (Nasdaq: DRRX) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and reasonable ...
Related articles »  
DURECT Corp (DRRX) Will Present POSIDUR Data at ASA Meeting
DURECT Corp (NASDAQ: DRRX) announced that data for POSIDUR (SABER-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at ANESTHESIOLOGY� 2014, the annual ...
DURECT Announces POSIDUR� (SABER�-Bupivacaine) Data Presentation at ...  PR Newswire (press release)
Related articles »  
DURECT Corporation (DRRX): Risk/Reward Remains Positive For Durect
On November 4, 2013, Durect Corp. (NASDAQ:DRRX) reported financial results for the third quarter 2013. The company reported total revenues in the quarter of $3.0 million, consisting of $2.6 million of product and excipient sales, mainly driven by sales ...
Related articles »  
Interview with the CFO: DURECT Corporation (DRRX)
Matthew J. Hogan, CFO, joined DURECT Corporation from Ciphergen Biosystems, where he was the Chief Financial Officer from 2000 to 2006 and a consultant from March 2006.
Durect Corporation - Insider Activity Report
Durect is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms.
Related articles »